home / stock / navb / navb news

NAVB News and Press, Navidea Biopharmaceuticals Inc. From 11/30/22

Stock Information
Company Name: Navidea Biopharmaceuticals Inc.
Stock Symbol: NAVB
Market: NYSE
Website: navidea.com
Menu
NAVB NAVB Quote NAVB Short NAVB News NAVB Articles NAVB Message Board
Get NAVB Alerts

News, Short Squeeze, Breakout and More Instantly...
NAVB - Navidea Biopharmaceuticals Files Appeal in CRG Case

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 2022, Navidea and its majority-owned subsidiary M...
NAVB - Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company's Phase 3 Trial in Rheumatoid Arthritis

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced enrollment of the 50 th participant in the Companyȁ...

NAVB - Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2022 Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2022 Earnings Conference Call November 15, 2022 5:00 PM ET Company Participants Michael Rosol – Chief Medical Officer Erika Eves – Vice President-Finance and Administration Conference Call Participants ...

NAVB - Navidea Biopharm GAAP EPS of -$0.25, revenue of $0.07M

Navidea Biopharm press release ( NYSE: NAVB ): Q3 GAAP EPS of -$0.25. Revenue of $0.07M (-92.8% Y/Y). For further details see: Navidea Biopharm GAAP EPS of -$0.25, revenue of $0.07M

NAVB - Navidea Biopharm GAAP EPS of -$0.25, revenue of $0.08M

Navidea Biopharm press release ( NYSE: NAVB ): Q3 GAAP EPS of -$0.25. Revenue of $0.08M (-91.8% Y/Y). Navidea ended the third quarter of 2022 with $4.6 million in cash and cash equivalents. Shares +1.92% PM. For further details see: Navidea Biopharm G...

NAVB - Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that results from the Company’s ongoing preclinical s...

NAVB - Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Joshua (“Josh”) Wilson to i...
NAVB - Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the results from the Company’s completed NAV3-31...

NAVB - Navidea Biopharmaceuticals, Inc. (NAVB) Q2 2022 Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NAVB) Q2 2022 Earnings Conference Call September 08, 2022, 04:00 PM ET Company Participants Michael Rosol – CMO Alex Cappello - Vice Chair Erika Eves - VP, Finance & Administration Conference Call Participants ...

NAVB - Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the opening of nine additional sites for recruitment into it...
Previous 10 Next 10